医药板块早盘走强，创新药ETF（159992）涨逾1%

Core Viewpoint - The A-share and Hong Kong stock markets are showing active performance in the innovative drug sector, with a notable increase in the innovative drug ETF following the release of the 2025 National Medical Insurance Drug List and the first version of the commercial insurance innovative drug list [1] Group 1: Market Performance - The innovative drug ETF (159992) rose approximately 1% as of 9:57 AM, with a trading volume exceeding 150 million yuan [1] - Leading stocks in the sector include Dizhe Pharmaceutical, Heng Rui Medicine, and Tigermed, while Tonghua Golden Horse, Renfu Pharmaceutical, and Te Bao Biological experienced slight declines [1] Group 2: Policy Developments - The 2025 National Medical Insurance Drug List successfully added 114 new drugs, including 50 innovative drugs, achieving an overall success rate of 88%, which is a significant increase from 76% in 2024 [1] - The first version of the commercial insurance innovative drug list includes 19 drugs, indicating a growing support for innovative drug development [1] Group 3: Industry Outlook - CITIC Securities believes that the record high success rate of national medical negotiations and the commercial insurance list will provide significant growth opportunities, encouraging the development of innovative drugs [1] - The international competitiveness of China's innovative drug pipeline is continuously improving, with evolving overseas strategies and new technologies driving rapid industry growth [1] - The innovative drug ETF closely tracks the CSI Innovative Drug Industry Index, selecting up to 50 representative listed companies to reflect the overall performance of the innovative drug sector [1]